1. A compound that is an inverse agonist of H3 receptors for use in slowing, stopping, or reversing the development of disability in multiple sclerosis (MS). 2. The compound of claim 1, wherein the compound is 1- {6 - [(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl) oxy] -3-pyridinyl} - 2-pyrrolidinone, 3- (benzo [d] [1,3] dioxol-5-yl) -5 - ((1-cyclobutylpiperidin-4-yl) methyl) -1,2,4-oxadiazole or 4- (4 - ((1-Isopropylpiperidin-4-yl) oxy) piperidin-1-yl) benzonitrile； or their pharmaceutically acceptable salts. 3. The compound of claim 2, wherein the compound is 1- {6 - [(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl) oxy] -3-pyridinyl} - 2-pyrrolidinone or a pharmaceutically acceptable salt thereof. 4. The compound according to any one of paragraphs. 1-3, in which the compound is administered orally to a person at a dose of 5-500 micrograms per day. The compound according to any one of paragraphs. 1-3, in which the compound is administered orally to a person at a dose of 10-150 micrograms per day. A compound that is an inverse agonist of H3 receptors for use in the treatment of demyelinating diseases, wherein the compound is 1- {6 - [(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7 -yl) hydroxy] -3-pyridinyl} -2-pyrrolidinone, 3- (benzo [d] [1,3] dioxol-5-yl) -5 - ((1-cyclobutylpiperidin-4-yl) methyl) -1 , 2,4-oxadiazole or 4- (4 - ((1-isopropylpiperidin-4-yl) oxy) piperidin-1-yl) benzonitrile； or their pharmaceutically acceptable salts. 7. The compound of claim 6, wherein the compound is 1- {6 - [(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl) oxy] -3-pyridinyl} - 2-pyrrolidinone or a pharmaceutically acceptable salt thereof. 8. A compound that is an inverse agonist of H3 receptors for use in stimulating demyelination, wherein the compound is 1- {6 - [(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7- il) oxy] -3-pyridinyl} -2-pyrrolidi1. Соединение, которое представляет собой обратный агонист H3-рецепторов, для применения в замедлении,
